Display options
Cite
Kentepozidis N, Economopoulou P, Liontos M, et al. Panitumumab in combination with modified docetaxel/cisplatin/5-fluorouracil as first-line treatment in gastric and gastroesophageal junction adenocarcinomas: a multicenter phase II study by the Hellenic Oncology Research Group. Ann Gastroenterol. 2018;31(6):698-704doi: 10.20524/aog.2018.0311.
Kentepozidis, N., Economopoulou, P., Liontos, M., Kotsakis, A., Boukovinas, I., Vardakis, N., Kontopodis, E., Prinarakis, E., Skaltsi, T., Souglakos, J., & Georgoulias, V. (2018). Panitumumab in combination with modified docetaxel/cisplatin/5-fluorouracil as first-line treatment in gastric and gastroesophageal junction adenocarcinomas: a multicenter phase II study by the Hellenic Oncology Research Group. Annals of gastroenterology, 31(6), 698-704. https://doi.org/10.20524/aog.2018.0311
Kentepozidis, Nikolaos, et al. "Panitumumab in combination with modified docetaxel/cisplatin/5-fluorouracil as first-line treatment in gastric and gastroesophageal junction adenocarcinomas: a multicenter phase II study by the Hellenic Oncology Research Group." Annals of gastroenterology vol. 31,6 (2018): 698-704. doi: https://doi.org/10.20524/aog.2018.0311
Kentepozidis N, Economopoulou P, Liontos M, Kotsakis A, Boukovinas I, Vardakis N, Kontopodis E, Prinarakis E, Skaltsi T, Souglakos J, Georgoulias V. Panitumumab in combination with modified docetaxel/cisplatin/5-fluorouracil as first-line treatment in gastric and gastroesophageal junction adenocarcinomas: a multicenter phase II study by the Hellenic Oncology Research Group. Ann Gastroenterol. 2018 Nov-Dec;31(6):698-704. doi: 10.20524/aog.2018.0311. Epub 2018 Sep 14. PMID: 30386120; PMCID: PMC6191861.
Copy Download .nbib Format: NLM
Share it on

Ann Gastroenterol. 2018 Nov-Dec;31(6):698-704. doi: 10.20524/aog.2018.0311. Epub 2018 Sep 14.

Panitumumab in combination with modified docetaxel/cisplatin/5-fluorouracil as first-line treatment in gastric and gastroesophageal junction adenocarcinomas: a multicenter phase II study by the Hellenic Oncology Research Group.

Annals of gastroenterology

Nikolaos Kentepozidis, Panagiota Economopoulou, Michael Liontos, Athanasios Kotsakis, Ioannis Boukovinas, Nikolaos Vardakis, Emmanouil Kontopodis, Efthimios Prinarakis, Teressa Skaltsi, John Souglakos, Vassilis Georgoulias

Affiliations

  1. Hellenic Oncology Research Group, Athens, Greece.

PMID: 30386120 PMCID: PMC6191861 DOI: 10.20524/aog.2018.0311

Abstract

BACKGROUND: A phase I/II study to define the maximum tolerated dose (MTD) of biweekly docetaxel/cisplatin/5-fluorouracil (DCF) plus panitumumab (P), its efficacy, and tolerability as first-line treatment in advanced gastroesophageal cancer.

METHODS: In phase I part, patients with unresectable locally advanced or metastatic adenocarcinomas of the stomach or the gastroesophageal junction received cisplatin (40 mg/m

RESULTS: The MTD for docetaxel in the mDCF/P was defined at 40 mg/m

CONCLUSIONS: mDCF/P combination was feasible, though associated with a poor toxicity profile. However, the study failed to meet its primary endpoint and was terminated prematurely due to futility.

Keywords: 5-fluorouracil; Gastroesophageal junction cancer; cisplatin; docetaxel; panitumumab ClinicalTrials.gov Identifier: NCT01716546

References

  1. J Clin Oncol. 2006 Nov 1;24(31):4991-7 - PubMed
  2. PLoS One. 2015 Aug 14;10(8):e0135599 - PubMed
  3. Biometrics. 1982 Mar;38(1):143-51 - PubMed
  4. Clin Cancer Res. 2007 Oct 1;13(19):5869-75 - PubMed
  5. Ann Oncol. 2000 Mar;11(3):301-6 - PubMed
  6. Ann Oncol. 2001 Jan;12(1):47-51 - PubMed
  7. J Clin Oncol. 2010 Nov 1;28(31):4706-13 - PubMed
  8. Med Oncol. 2014 Oct;31(10):226 - PubMed
  9. Am J Clin Oncol. 2000 Aug;23(4):341-4 - PubMed
  10. J Natl Cancer Inst. 2015 Dec 30;108(6):djv394 - PubMed
  11. BMC Gastroenterol. 2015 Feb 05;15:7 - PubMed
  12. J Clin Oncol. 2007 Aug 1;25(22):3205-9 - PubMed
  13. Eur J Cancer. 2009 Jan;45(2):228-47 - PubMed
  14. J Clin Pathol. 2014 Apr;67(4):307-12 - PubMed
  15. Lancet. 2011 Jun 18;377(9783):2103-14 - PubMed
  16. Br J Cancer. 2016 Mar 1;114(5):505-9 - PubMed
  17. Ann Surg Oncol. 2008 Jan;15(1):69-79 - PubMed
  18. J Clin Oncol. 2010 Nov 1;28(31):4697-705 - PubMed
  19. J Clin Oncol. 2011 Mar 1;29(7):868-74 - PubMed
  20. Int J Oncol. 2012 Apr;40(4):975-82 - PubMed
  21. Jpn J Clin Oncol. 2002 Jul;32(7):248-54 - PubMed
  22. Lancet Oncol. 2013 May;14(6):490-9 - PubMed
  23. Ann Oncol. 2011 Jun;22(6):1367-73 - PubMed
  24. J Clin Oncol. 2007 May 1;25(13):1658-64 - PubMed
  25. Oncogene. 2016 Jun 9;35(23):2949-60 - PubMed
  26. Lancet. 2010 Aug 28;376(9742):687-97 - PubMed
  27. Ann Oncol. 2014 May;25(5):1039-44 - PubMed
  28. PLoS One. 2014 Nov 05;9(11):e111693 - PubMed
  29. Ann Oncol. 2007 Mar;18(3):510-7 - PubMed
  30. Am J Clin Oncol. 2017 Dec;40(6):543-551 - PubMed
  31. Lancet Oncol. 2013 May;14(6):481-9 - PubMed
  32. Ann Oncol. 2014 Jan;25(1):107-16 - PubMed

Publication Types